Creating new safe and efficacious immunotherapies for patients
Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. This approach leverages a natural immune response with innovative protein engineering to achieve a more controlled immune response providing greater patient benefit while reducing toxicity — areas that have traditionally challenged broadly-acting immunotherapies on the market. In a push to move new safe and efficacious immunotherapies to patients, Cue Biopharma has scaled and grown into a clinical-stage company by expanding its development work in-house.
Challenges
| Non-standardized data capture | Excel sheets were flexible but difficult to manage at scale. This led to tedious data reconciliation when attempting larger analysis. |
|---|---|
| Barriers to communication and handoffs between teams | Rapid scaling, combined with the difficulty inherent in bridging research and development, led to collaboration challenges. |
| Growing into early development | Cue Biopharma wanted to evolve into a clinical-stage organization and needed to put in place the digital infrastructure necessary to do so. |
Outcomes
| Generating R&D insights | Consistent, structured data capture in templates allowed deeper insights to be drawn across experiments. |
|---|---|
| Cross-team collaboration | Collaboration and handoffs between teams - particularly between research and development - are efficient and effortless. |
| Centralized project management | Cue Biopharma is clinical-stage ready and has a 360-degree view of scientific progress driving outcomes. |
